SAN DIEGO, CA: Genection, a global genomics company and a subsidiary of Invivoscribe Technologies has unveiled MyAML, a CLIA validated next gen sequencing assay that identifies mutations across 194 genes that are associated with acute myeloid leukemia (AML).

The MyAML includes single nucleotide variants (SNVs), insertion-deletion variants (indels) and the entire range of structural variants. Besides this, the panel also comprises partial tandem duplications (PTDs) and translocations.

MyAML identifies the underlying somatic mutations that are present in a minimum of 5 percent allelic frequency. The data and report includes single base resolution of the genomic breakpoint and sequences of mutations, which facilitates both minimal residual disease testing and temporal and longitudinal studies.

MyAML is used by clinical partners and pharmaceutical companies to better define treatment, stratify patients for enrollment in clinical trials, and differentiate AML responder and non-responder populations in retrospective analyses. The test is immediately available through Invivoscribe's accredited laboratories in the United States and Europe.

"Acute myeloid leukemia afflicts tens of thousands of patients worldwide annually. MyAML™ reveals both the predominant driver mutations and the subclonal architecture of genomic mutations that recur in AML, providing clinicians with the best prognostic tool to stratify patients and direct patient care, expand and better define therapeutic options, and identify the appropriate clinical trials for their patients. Precision medicine is a reality today," says Bradley Patay, MD and Chief Medical Officer of Genection